Netherlands Cancer Institute at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Netherlands Cancer Institute takes part in 17 sessions at ESMO 2026 in Madrid. Its program centres on immunotherapy, with neoadjuvant treatment in melanoma, organ preservation in cutaneous squamous cell carcinoma and new immune approaches in kidney cancer. Other sessions cover tumour-agnostic trial design, access to clinical trials, triple-negative early breast cancer, gynaecological sarcomas and personalised breast cancer prevention.
| Organization | ESMO 2026 Attendance |
|---|---|
Netherlands Cancer Institute Amsterdam, Netherlands | |
Cancer research institute with its own cancer hospital in Amsterdam, Netherlands. | Chair Fri Oct 23 16:15–17:45 Raising the bar for tumor-agnostic studies Biomarkers & precision oncology Talk Fri Oct 23 16:45–17:00 Tumor agnostic drug repurposing trials: Boost or brake? Biomarkers & precision oncology Chair Sat Oct 24 08:30–10:00 Chair Sat Oct 24 10:15–11:30 Multidisciplinary insights for effective care in gynaecological sarcomas Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 10:15–10:35 Talk Sat Oct 24 10:15–10:35 Treating for two: Immunotherapy, targeted therapy, and other treatments in pregnancy Melanoma & skin cancers Talk Sat Oct 24 10:50–11:05 Local treatment: Surgery (LMS/HGUS/ESS) Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 12:19–12:26 Talk Sat Oct 24 14:45–15:05 Chair Sat Oct 24 14:45–16:15 Abstract Sat Oct 24 17:06–17:18 Invited Discussant LBA2 Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Chair Sun Oct 25 10:15–11:45 Talk Sun Oct 25 10:35–10:55 Novel immunotherapy; CAR-T, Bispecific antibodies, New ICIs Genitourinary cancers Abstract Sun Oct 25 10:52–10:57 Abstract Sun Oct 25 11:14–11:19 Abstract Sun Oct 25 11:33–11:45 Chair Sun Oct 25 16:30–18:00 Peri-operative management of urothelial cancer Genitourinary cancers Chair Sun Oct 25 16:30–18:00 Abstract Mon Oct 26 09:29–09:34 3724RO - Patient reported outcomes (PROs) with varegacestat versus placebo (PBO) in progressing desmoid tumors: Results from RINGSIDE Part B Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 10:20–10:25 4250RO - High affinity FcγR3A germline SNP impairs outcome upon anti-PD1 in melanoma Biomarkers & precision oncology Chair Mon Oct 26 14:45–16:15 Abstract Mon Oct 26 15:00–15:12 Talk Mon Oct 26 15:25–15:45 |
Instantly find 20 buyers from Netherlands Cancer Institute
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction